Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy

References

1. 1.↵
   2. Kendler DL,
   3. Lippa J,
   4. Rootman J

   . The initial clinical characteristics of Graves' orbitopathy vary with age and sex. Arch Ophthalmol 1993;111:197–201 doi:10.1001/archopht.1993.01090020051022 pmid:8431156

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Winand RJ,
   3. Cornet G,
   4. Etienne-Decerf J, et al

   . Original acquisition in the pathogenesis and the treatment of endocrine ophthalmopathy. Metab Pediatr Syst Ophthalmol 1988;11:126–32 pmid:3205167

   PubMed
3. 3.↵
   2. Kahaly G,
   3. Hansen C,
   4. Beyer J, et al

   . Plasma glycosaminoglycans in endocrine ophthalmopathy. J Endocrinol Invest 1994;17:45–50 doi:10.1007/BF03344962 pmid:8006327

   CrossRefPubMed
4. 4.↵
   2. Ludgate M,
   3. Baker G

   . Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 2002;127:193–98 doi:10.1046/j.1365-2249.2002.01792.x pmid:11876739

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Rundle FF,
   3. Wilson CW

   . Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 1945;5:177–94 pmid:21011937

   PubMed
6. 6.↵
   2. Claridge KG,
   3. Ghabrial R,
   4. Davis G, et al

   . Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye 1997;11:717–22 doi:10.1038/eye.1997.183 pmid:9474324

   CrossRefPubMed
7. 7.↵
   2. Mayer EJ,
   3. Herdman G,
   4. Burnett C, et al

   . Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid disease. Eye 2001;15:313–18 doi:10.1038/eye.2001.102 pmid:11450728

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Kahaly GJ

   . Imaging in thyroid-associated orbitopathy. Eur J Endocrinol 2001;145:107–18 doi:10.1530/eje.0.1450107 pmid:11454505

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Feldon SE,
   3. Lee CP,
   4. Muramatsu SK, et al

   . Quantitative computed tomography of Graves' ophthalmopathy: extraocular muscle and orbital fat in development of optic neuropathy. Arch Ophthalmol 1985;103:213–15 doi:10.1001/archopht.1985.01050020065021 pmid:3838463

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Peyster RG,
    3. Ginsberg F,
    4. Silber JH, et al

    . Exophthalmos caused by excessive fat: CT volumetric analysis and differential diagnosis. AJR Am J Roentgenol 1986;146:459–64 doi:10.2214/ajr.146.3.459 pmid:3484861

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Fang ZJ,
    3. Zhang JY,
    4. He WM

    . CT features of exophthalmos in Chinese subjects with thyroid-associated ophthalmopathy. Int J Ophthalmol 2013;6:146–49 doi:10.3980/j.issn.2222-3959.2013.02.07 pmid:23638413

    CrossRefPubMed
12. 12.↵
    2. Nishida Y,
    3. Tian S,
    4. Isberg B, et al

    . Significance of orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 2002;240:515–20 doi:10.1007/s00417-002-0498-3 pmid:12136278

    CrossRefPubMed
13. 13.↵
    2. Kvetny J,
    3. Puhakka KB,
    4. Rohl L

    . Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associated ophthalmopathy and proptosis. Acta Ophthalmol Scand 2006;84:419–23 doi:10.1111/j.1600-0420.2005.00617.x pmid:16704711

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Prummel MF,
    3. Gerding MN,
    4. Zonneveld FW, et al

    . The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2001;54:205–09 doi:10.1046/j.1365-2265.2001.01220.x pmid:11207635

    CrossRefPubMed
15. 15.↵
    2. Mayer EJ,
    3. Fox DL,
    4. Herdman G, et al

    . Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol 2005;56:20–24 doi:10.1016/j.ejrad.2005.03.027 pmid:15896938

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Comerci M,
    3. Elefante A,
    4. Strianese D, et al

    . Semiautomatic regional segmentation to measure orbital fat volumes in thyroid-associated ophthalmopathy: a validation study. Neuroradiol J 2013;26:373–79 doi:10.1177/197140091302600402 pmid:24007725

    Abstract/FREE Full Text
17. 17.↵
    2. Higashiyama T,
    3. Nishida Y,
    4. Ohji M

    . Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy. Jpn J Ophthalmol 2015;59:430–35 doi:10.1007/s10384-015-0410-4 pmid:26321629

    CrossRefPubMed
18. 18.↵
    2. Hu HH,
    3. Kim HW,
    4. Nayak KS, et al

    . Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity (Silver Spring) 2010;18:841–47 doi:10.1038/oby.2009.352 pmid:19834463

    CrossRefPubMed
19. 19.↵
    2. Takasu M,
    3. Tani C,
    4. Sakoda Y, et al

    . Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results. Eur Radiol 2012;22:1114–21 doi:10.1007/s00330-011-2351-8 pmid:22138735

    CrossRefPubMed
20. 20.↵
    2. Bartalena L,
    3. Baldeschi L,
    4. Dickinson A, et al

    ; European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273–85 doi:10.1530/EJE-07-0666 pmid:18299459

    FREE Full Text
21. 21.↵
    2. Tian S,
    3. Nishida Y,
    4. Isberg B, et al

    . MRI measurements of normal extraocular muscles and other orbital structures. Graefes Arch Clin Exp Ophthalmol 2000;238:393–404 doi:10.1007/s004170050370 pmid:10901470

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Hoh HB,
    3. Laitt RD,
    4. Wakely C, et al

    . The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease. Eye 1994;8:506–10 doi:10.1038/eye.1994.126 pmid:7835442

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Laitt RD,
    3. Hoh B,
    4. Wakeley C, et al

    . The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol 1994;67:244–47 doi:10.1259/0007-1285-67-795-244 pmid:8130995

    Abstract/FREE Full Text
24. 24.↵
    2. Bailey CC,
    3. Kabala J,
    4. Laitt R, et al

    . Magnetic resonance imaging in thyroid eye disease. Eye 1996;10:617–19 doi:10.1038/eye.1996.140 pmid:8977792

    CrossRefPubMed
25. 25.↵
    2. Higashiyama T,
    3. Nishida Y,
    4. Morino K, et al

    . Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy. Jpn J Ophthalmol 2015;59:124–30 doi:10.1007/s10384-014-0365-x pmid:25448468

    CrossRefPubMed
26. 26.↵
    2. Bartalena L,
    3. Baldeschi L,
    4. Dickinson AJ, et al

    . Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008;18:333–46 doi:10.1089/thy.2007.0315 pmid:18341379

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Kauppinen-Mäkelin R,
    3. Karma A,
    4. Leinonen E, et al

    . High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2002;80:316–21 doi:10.1034/j.1600-0420.2002.800316.x pmid:12059873

    CrossRefPubMed
28. 28.↵
    2. van Geest RJ,
    3. Sasim IV,
    4. Koppeschaar HP, et al

    . Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008;158:229–37 doi:10.1530/EJE-07-0558 pmid:18230831

    Abstract/FREE Full Text
29. 29.↵
    2. Bahn RS,
    3. Heufelder AE

    . Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468–75 doi:10.1056/NEJM199311113292007 pmid:8413459

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Watanabe N,
    3. Noh JY,
    4. Kozaki A, et al

    . Radioiodine-associated exacerbation of Graves' orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 2015;100:2700–08 doi:10.1210/jc.2014-4542 pmid:25965082

    CrossRefPubMed
31. 31.↵
    2. Hiromatsu Y,
    3. Kojima K,
    4. Ishisaka N, et al

    . Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992;2:299–305 doi:10.1089/thy.1992.2.299 pmid:1493371

    CrossRefPubMed
32. 32.↵
    2. Just M,
    3. Kahaly GJ,
    4. Higer HP, et al

    . Graves ophthalmopathy: role of MR imaging in radiation therapy. Radiology 1991;179:187–90 doi:10.1148/radiology.179.1.2006276 pmid:2006276

    CrossRefPubMed
33. 33.↵
    2. Ohnishi T,
    3. Noguchi S,
    4. Murakami N, et al

    . Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology 1994;190:857–62 doi:10.1148/radiology.190.3.8115640 pmid:8115640

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Kendall-Taylor P,
    3. Crombie AL,
    4. Stephenson AM, et al

    . Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988;297:1574–78 doi:10.1136/bmj.297.6663.1574 pmid:2906260

    Abstract/FREE Full Text
35. 35.↵
    2. Bartalena L,
    3. Marcocci C,
    4. Bogazzi F, et al

    . Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349–52 doi:10.1056/NEJM198911163212001 pmid:2811943

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Potgieser PW,
    3. Wiersinga WM,
    4. Regensburg NI, et al

    . Some studies on the natural history of Graves' orbitopathy: increase in orbital fat is a rather late phenomenon. Eur J Endocrinol 2015;173:149–53 doi:10.1530/EJE-14-1140 pmid:26142100

    Abstract/FREE Full Text
37. 37.↵
    2. Costa DN,
    3. Pedrosa I,
    4. McKenzie C, et al

    . Body MRI using IDEAL. AJR Am J Roentgenol 2008;190:1076–84 doi:10.2214/AJR.07.3182 pmid:18356458

    CrossRefPubMed
38. 38.↵
    2. Gerdes CM,
    3. Kijowski R,
    4. Reeder SB

    . IDEAL imaging of the musculoskeletal system: robust water fat separation for uniform fat suppression, marrow evaluation, and cartilage imaging. AJR Am J Roentgenol 2007;189:284–91 pmid:17954627

    CrossRefPubMed
39. 39.↵
    2. Humbert IA,
    3. Reeder SB,
    4. Porcaro EJ, et al

    . Simultaneous estimation of tongue volume and fat fraction using IDEAL-FSE. J Magn Reson Imaging 2008;28:504–08 doi:10.1002/jmri.21431 pmid:18666214

    CrossRefPubMed